… with bevacizumab showed better overall progression-free survival benefits compared with
… are warranted to move rationally designed AR-targeted therapies forward into the clinic to …

… androgen receptor with high affinity and blocking androgen … (ENZa) can prolong survival
time for patients with mCRPC [7,8… targets interaction profile but with higher affinity and better …

… of this receptor and has led to the development of rational drug … Early ligand-based drug
design was based on modification … The complexity of PROTAC design has increased as more …

… proteins have not been amenable as therapeutic targets. … of therapy has led to significant
improvement in overall survival… -molecule databases and rational design of molecules may help …

… With increased knowledge of androgen receptor structure … treatments will stimulate
research and drug discovery for … prolonged survival demonstrates the power of rational drug …

… a rapid, but transient increase in serum LH and hence, testosterone levels – termed a '…
These findings provided the rational for drug discovery screens to identify novel anti-androgens …

… the development of AR-targeted therapies to improve survival … from AR-targeted therapies
and how to develop rational … needs to be explored to support further drug development. …

… to increased androgen receptor protein … therapies targeting continued AR signaling in
tumors despite these agents remain urgent drug development priorities, as does the development …

… binding of cognate natural ligands, allowing rational drug design for the treatment of PCa.
First of … Median metastasis-free survival increased from 16.2 months in the control arm to 40.5 …

… Fortunately, improved breast cancer survival is correlated with AR expression (54), which
occurs in up to 85% of ER-positive breast cancers and 95% of ER-negative breast cancers (55)…